MANUFACTURING ARTICLES

• Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next

  Oligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.

• Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026

  Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond. 

• To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem

  The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.

• Striking The Right Balance: The Critical Discussions Driving The mRNA Industry's Next Chapter

  Now, I cannot claim that I or any of the panelists at CASSS have or had access to a real crystal ball that will show us the future. However, what did come through these discussions loud and clear is that the future of our industry must include “balance.” Here, I’ll unpack a few ways the theme of “balance” presented itself — and no doubt will continue to present itself in the future — as well as how the panelists see us achieving this necessary balance. 

• Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing

  Here, a panel of experts at the RNA Leaders Conference gives a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.” 

• From Misinformation To Medicine: Forging Bipartisan Support to Reverse Anti-mRNA Policy

  In this article, I’ll share some of the progress AMM has made and the barriers the organization/our industry is still facing in our efforts to reverse the policy decisions that have been made against mRNA today. Throughout the panel, the speakers also shared their thoughts on the types of messaging we should be considering and/or have started to see making an impact.